Non-Small Cell Lung Cancer Market

Reena kumari

January 12th, 2026
No Comments
3:11 PM

This report presents a detailed, data-driven analysis of the global Non-Small Cell Lung Cancer Market size, offering insights into historical performance, current dynamics, and projections from 2025 to 2035. With a strong emphasis on factual assessment, the report refrains from speculative assumptions and aims to support business decisions through accurate forecasting and strategic intelligence.

I recently came across a report by Roots Analysis that really put things into perspective. According to them, the global non-small cell lung cancer market size is estimated to grow from USD 18.56 billion in 2024 to USD 19.78 billion in 2025 and USD 37.49 billion by 2035, representing a CAGR of 6.60% during the forecast period.

Market Segmentation

– Key Report Attributes
– Historical Trend
– Forecast Period
– Market Size Value by 2025
– Market Size Value by 2035
– CAGR (Till 2035)

Key Geographies

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

Each segment is analyzed by volume, value, and growth patterns, offering a comparative understanding of usage trends and market opportunities.

Recent Developments in Non-Small Cell Lung Cancer Market

Several recent developments have taken place in the field of non-small cell lung cancer treatment, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall non small cell lung cancer market trends detailed in our analysis.

In April 2025, Novocure received the CE approval for its wearable medical devices, Optune Lua® for the treatment of adult patients with metastatic NSCLC.
In April 2025, Summit Therapeutics entered into a licensing agreement with Akeso, under which Summit made an upfront payment of $500 million to acquire the rights to develop and commercialize Akeso’s experimental PD-1/VEGF bispecific antibody, ivonescimab.
In March 2025, the European Lung Cancer Congress (ELCC) held a conference with global experts to discuss the latest advances in the prevention, diagnosis, and management of thoracic malignancies, with a strong focus on non small cell lung cancer, in Paris, France.

Non-small Cell Lung Cancer Market Share Insights

Market Share by Type of Cancer: Adenocarcinoma Industry Holds the Largest Share

The non small cell lung cancer market forecast is categorized into various sub-segments based on the type of cancer, such as squamous cell carcinoma, adenocarcinoma, large cell neuroendocrine tumors, and large-cell carcinoma. In 2025, the adenocarcinoma (>45%) sub-segment dominates the market.
The increasing research on combination therapies and immunotherapies (including immune checkpoint inhibitors) for targeting adenocarcinoma has contributed to the high market share.
Our in-house experts anticipate the squamous cell carcinoma market to grow at a higher CAGR during the forecast period, owing to the presence of squamous thin, flat cells that look like fish scales present in the inside wall of alveolar sacs of lungs. The high exposure to ultraviolet radiation can result in mutations and cause squamous cell carcinoma.

Market Share by Type of Molecule: Small Molecules Hold the Largest NSCLC Market Share

There are various sub-segments of non small cell lung cancer market analysis based on the type of molecules, such as small molecules and biologics. Currently, small molecules account for the highest share of the market, due to the growing shift towards combination therapies wherein researchers develop targeted therapies using small molecules and chemotherapy.
In the long run, biologics will grow at a significant CAGR driven by the growing trend of oncology precision medicines for the treatment of patients with lung carcinoma.

Market Share by Drug Class: Drugs with Epidermal Growth Factor Receptor (EGFR) Inhibitors Hold the Largest Share within Non Small Cell Lung Cancer Market

Within the market for non small cell lung cancer therapeutics, drug classes, such as alkylating agents, antimetabolites, EGFR inhibitors, mitotic inhibitors, multi-kinase inhibitors and other drug classes, define various sub-segments. EGFR inhibitors currently account for the highest non-small cell lung cancer market share, and this trend is unlikely to change in the coming years.
EGFR inhibitors have shown significant potential to target epidermal growth factor receptor pathway, which slows cancerous cell proliferation. The growing demand for personalized treatment based on biomarkers status and development of next-generation inhibitors have contributed to the highest share of EGFR inhibitors.

Key Players Include:

Andermatt
Bayer
BioSafe Systems
Certis Biologicals
Corteva Agriscience
Novozymes
Nutri-Tech Solutions
ProFarm
Syngenta
Valent Biosciences

These companies are assessed based on their contributions to market share, innovation, and responsiveness to global and regional demand shifts.

Regional Insights

Each region is evaluated based on:

Historical market trends and sales data
Regulatory frameworks
Product availability and distribution strength
Emerging opportunities and constraints

Comparative regional analysis enables better targeting of expansion strategies and investment planning.

Supply Chain & Operational Overview

This section covers:

Pricing structures
Distribution channels
Manufacturing capabilities
Cost breakdowns and logistics trends

Understanding operational flows adds value to strategic sourcing and capacity expansion discussions.

Research Methodology

This report is developed using a combination of:

Primary research: Expert interviews, corporate disclosures
Secondary research: Company websites, public filings, databases, and published literature

All data points were reviewed for consistency, ensuring neutrality, reliability, and practical relevance for stakeholders and strategic planners.

Conclusion and Customization

This Non-Small Cell Lung Cancer Market report serves as a foundational reference for:

Market entry and expansion strategies
Product development roadmaps
Investment decision-making

For custom data slices or tailored analysis by geography, product, or competitor, please contact [email protected].

About Roots Analysis

Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors.

Why Use Roots Analysis in era of Artificial Intelligence?

Tailored Insights
Robust Methodology
Smart Decisions Made Easy

By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry.

Services Offered:

Consulting Services (custom insights supporting strategic and tactical requirements, off-the-shelf ready to consume work)

Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors.

They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans.

Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation.

Subscription Services (bundled services supporting multiple topics and domains for a firm)

With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats.

The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively.

Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights.

Contact Details for Roots Analysis

Chief Executive: Gaurav Chaudhary

Email: [email protected]

Website: https://www.rootsanalysis.com/